

Supplementary Table 5. Odds ratios for the hepatic fibrosis stages according to u-NCR in insulin users ($n=300$)

Model	Hepatic fibrosis stage 2 (F2)		Hepatic fibrosis stage 3 (F3+4)	
	aOR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value
1	2.12 (1.28–3.52)	0.004 ^a	2.16 (1.44–3.24)	<0.001 ^a
2	2.09 (1.26–3.46)	0.004 ^a	1.95 (1.29–2.95)	0.002 ^a
3	2.08 (1.24–3.49)	0.006 ^a	2.01 (1.32–3.06)	0.001 ^a
4	2.00 (1.15–3.47)	0.014 ^a	2.18 (1.39–3.42)	0.001 ^a

Model 1 was adjusted for age, male sex, body mass index, and duration of diabetes; Model 2 adjusted for Model 1 parameters plus hypertension, lipid medication; Model 3 adjusted for Model 2 parameters plus triglyceride, alanine aminotransferase; Model 4 adjusted for Model 3 parameters plus glycosylated hemoglobin, insulin.

u-NCR, urinary *N*-acetyl-β-D-glucosaminidase to creatinine ratio; aOR, adjusted odds ratio; CI, confidence interval.

^aStatistical significance at $P < 0.05$.